Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | EYA2 | O00167 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6670969 | 0.95 | KDM4E (0.45) | L3MBTL1KDM4EALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7645327 | 0.94 | KDM4E (0.44) | L3MBTL1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL8326095 | 0.94 | KDM4E (0.44) | L3MBTL1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL8421338 | 0.94 | PTGS2 (0.48) | KDM4EALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL8321067 | 0.85 | POLB (0.47) | KDM4EALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL9829521 | 0.82 | ALDH1A1 (0.50) | L3MBTL1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL7093072 | 0.81 | KDM4E (0.37) | L3MBTL1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL8421829 | 0.81 | TSHR (0.50) | L3MBTL1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL8325647 | 0.80 | KMT2A (0.40) | KDM4EALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL7111544 | 0.78 | TSHR (0.50) | L3MBTL1KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259928-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ZHANG HAN-CHENG (US) | 2004-12-23 | — | — | US | claimed |
| US-20040228889-A1 | Use of N-arylmethylene ethylenediaminetriacetates, N-arylmethylene iminodiacetated or N,N'-diarylmethylene ethylenediamineacetates as doners of NO | L'OREAL S.A. (FR) | 2004-11-18 | — | — | US | claimed |
| EP-0668854-B1 | USE OF N-ARYLMETHYLENE, ETHYLENEDIAMINETRIACETATES N-ARYLMETHYLENE IMINODIACETATES OR N,N'-DIARYLMETHYLENE ETHYLENEDIAMINACETATES FOR USE IN COMBATTING OXIDATIVE STRESS | OREAL (FR) | 1999-10-13 | — | — | EP | claimed |
| US-5629436-A | Use of N-arylmethylene ethylenediaminetriacetates N-arylmethylene iminodiacetates or N,N'-diarylmethylene ethylenediamineacetates against oxidative stress | L'OREAL (FR) | 1997-05-13 | — | — | US | claimed |
| US-20040259928-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ZHANG HAN-CHENG (US) | 2004-12-23 | — | — | US | disclosed |
| US-20040228889-A1 | Use of N-arylmethylene ethylenediaminetriacetates, N-arylmethylene iminodiacetated or N,N'-diarylmethylene ethylenediamineacetates as doners of NO | L'OREAL S.A. (FR) | 2004-11-18 | — | — | US | disclosed |
| US-20040220260-A1 | Use of mono-or di-esters of cinnamic acid or of one of its derivatives and vitamin C, as donor of NO | L'OREAL S.A. (FR) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259928-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | MAP2K2, MAP3K20, MAP3K1 | L3MBTL1 1714/4885KDM4E 1536/4885ALDH1A1 3103/4885 |
| US-20040220260-A1 | Use of mono-or di-esters of cinnamic acid or of one of its derivatives and vitamin C, as donor of NO | ME2, ADH7, ME3 | L3MBTL1 4707/4885KDM4E 3156/4885ALDH1A1 199/4885 |
| US-20040228889-A1 | Use of N-arylmethylene ethylenediaminetriacetates, N-arylmethylene iminodiacetated or N,N'-diarylmethylene ethylenediamineacetates as doners of NO | NNMT, HNMT, PNMT | L3MBTL1 4805/4885KDM4E 1882/4885ALDH1A1 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.